On April 13, 2026 LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, reported the presentation of preliminary results for a clinical trial testing the combination of Lixte’s proprietary compound LB100 in combination with Dostarlimab at the 2026 Conference of the Society of Gynecological Cancer, April 10-13, in San Juan, Puerto Rico.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The annual conference brings together a diverse group of specialists, including gynecologic oncologists, radiation oncologists, nurses, researchers and others to share the latest scientific advancements. It features exhibitors from various medical device and pharmaceutical companies, showcasing cutting-edge products and services tailored for the gynecologic cancer care team.

"The findings being presented provide new hope for patients with ovarian cancer, a disease that thus far has limited therapeutic options," said Bas van der Baan, LIXTE’s Chief Scientific Officer. "LIXTE’s proprietary compound, LB-100, combined with GSK’s anti PD1 drug Dostarlimab, has shown an acceptable safety profile. All 21 planned participants in the trial have been enrolled, and 20 were evaluated for efficacy in this interim analysis. Based on those favorable results, an additional cohort of 21 patients with a higher exposure to LB-100 is in the process of enrolling."

Trial Results

At a median follow-up length of 12 months (range 1.4-22), median OS has not been reached. However, OS probability was 0.84 (95%CI 0.64-0.94) at 6 months and 0.69 (95% CI 0.44-0.84) at 12 months. The Disease Control Rate was 40% (8/20, 95% CI 19.1-63.9%).

The trial is based on the observation by the lead clinical investigator Amir Jazaeri MD, Professor of Gynecologic Oncology at The University of Texas MD Anderson Cancer Center, that a genetically acquired reduction in PP2A activity may increase responsiveness to immune checkpoint blockade (ICB) in Ovarian Clear Cell Carcinoma (OCCC), particularly in tumors harboring somatic PPP2R1A mutations resulting in loss of protein phosphatase 2A (PP2A) function.

"We are learning more about the molecular features of ovarian clear-cell carcinomas that correlate with benefit from immune checkpoint inhibitors," said Dr. Jazaeri. "This study investigates how to use immunotherapy combinations such as Dostarlimab and LB-100 to expand the benefit for patients whose tumors do not carry these features."

Specifically, prior investigation reported markedly prolonged overall survival (OS) with ICB in patients with PPP2R1A-mutant OCCC (66.9 months versus 9.2 months for patients with wild-type tumors). This suggested that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with Ovarian Clear Cell Carcinoma lacking the genetic reduction in PP2A.

(Press release, Lixte Biotechnology, APR 13, 2026, View Source [SID1234664343])

On April 13, 2026 ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic therapy (VTP) to treat a range of solid tumors, reported positive preliminary results from the Company’s ongoing Phase 1 study of Padeliporfin VTP treatment in patients with unresectable locally advanced pancreatic ductal adenocarcinoma (LA-PDAC). These data will be shared in a late-breaking podium presentation at the Society of Interventional Radiology (SIR) 2026 Annual Meeting taking place April 11-15, 2026 in Toronto, Canada. Early clinical observations of Padeliporfin in LA-PDAC support advancement of the program, while the Company is pursuing strategic partnering opportunities to support the commercialization of its low-grade upper tract urothelial carcinoma (UTUC) program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These initial results from our ongoing trial in LA-PDAC spotlight the emerging clinical profile behind our strategic advancement of this program. At the lowest dose, Padeliporfin VTP has so far not only demonstrated a well-tolerated profile – consistent with the robust body of data generated across indications – but, importantly, also shown promising signs of clinical efficacy highlighting its potential to convert patients with unresectable tumors to become eligible for surgery," said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. "For such a large, high-need set of patients with limited treatment options aside from surgery, Padeliporfin VTP has the potential to expand the treatable population by selectively ablating the tumor near major arteries to safely allow for resection of the residual tumor tissue. We are strongly encouraged by the initial responses from the first cohort and look forward to providing additional updates on the program this year."

The Phase 1 LA-PDAC trial is a two-part dose-escalation and expansion study evaluating Padeliporfin VTP in patients with vascular encasement deeming them ineligible for surgical resection. The primary objective in Part A of this trial is to assess safety and determine the optimal light dose to progress into Part B for further evaluation. Secondary objectives are to assess preliminary efficacy, as patients are evaluated following treatment to determine eligibility for pancreaticoduodenectomy (Whipple procedure).

As of December 4, 2025, the data cut-off for the podium presentation at SIR, three patients had completed follow-up from initial treatment in the lowest dose cohort (200 mW/cm) and were evaluable for potential surgery.

Key preliminary results from the Phase 1 study of Padeliporfin VTP in LA-PDAC:

Clinical Profile:

2 of the 3 (66%) patients successfully underwent surgery following Padeliporfin VTP treatment with low light dose of 200 mW/cm, with the third patient remaining ineligible for surgery due to a mesenteric tumor spread unrelated to the VTP procedure.

Safety and Tolerability Profile:

Padeliporfin VTP was well-tolerated with no complications observed related to arterial injury, thrombosis, ischemia, or other VTP-related morbidity, consistent with previous data obtained from prior clinical studies.
No select treatment-related adverse effects (sTRAE) or dose-limiting toxicities (DLT) were observed in any patients.

ImPact has completed patient enrollment in the second cohort of the Phase 1 dose-escalation study and expects to report additional data throughout 2026. Subject to future discussions with the U.S. Food and Drug Administration (FDA), the Company believes the program may have potential to move directly into a registrational study.

"Given PDAC’s large addressable market and potential for an efficient development path forward, this program represents a compelling near-term opportunity for ImPact," said Barak Palatchi, Chief Executive Officer of ImPact Biotech. "The significant platform potential demonstrated by Padeliporfin VTP across several indications has enabled us to strategically pursue opportunities with the greatest potential for patient impact and long-term value. While we continue to generate promising and validating results with our late-stage UTUC program, we believe that advancing this program with the right strategic partner, supported by a commercial infrastructure and resources to accelerate launch, will maximize its impact for patients and allow our team and resources to focus on what we do best."

Topline data from the Phase 3 ENLIGHTED trial in low-grade upper tract urothelial carcinoma (UTUC) and submission of a new drug application (NDA) for Padeliporfin VTP to the FDA are anticipated in 2026.

Presentation Details:

Title: Intra-Arterial (IA) Padeliporfin Vascular-Targeted Photodynamic Therapy (VTP): Ongoing Multicenter, Phase I Light Dose Escalation Study in Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC)

Presenter: Nadine Abi-Jaoudeh, M.D., Professor of Radiology, University of California, Irvine
Session Title: Late-breaking Abstracts 2
Session Date & Time: Monday, April 13, 2026, 4:21 PM ET

About PDAC
Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer deaths, with a five-year survival rate of approximately 10% – the lowest among all solid tumors. At diagnosis, only about 20% of patients have resectable or borderline resectable disease, while the remaining 80% present with unresectable tumors that are either locally advanced or have distant metastases. Patients with unresectable tumors have limited therapeutic options and while prognoses have improved significantly in the last decade, only about 5% of patients will survive for 10 years or more following diagnosis. Therapeutic options for treatable patients remain limited and underscore significant unmet need for innovative treatments that can improve survival and quality of life.

(Press release, ImPact Biotech, APR 13, 2026, View Source [SID1234664342])

On April 13, 2026 Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, reported that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Lu will participate in an educational session titled "Engineered NK Cells: From Innate Immunity to Clinical Innovation." The session will highlight advances in the development of Senti’s engineered Logic-Gated SENTI-202 cell therapy and the broader potential for Logic Gates to address a wide range of unmet needs in oncology.

Presentation Details:

Session Title: Engineered NK Cells: From Innate Immunity to Clinical Innovation
Session Type: Educational Session
Presenter: Timothy Lu, Co-Founder & CEO, Senti Biosciences
Date: Friday, April 17, 2026
Time: 3:00 – 4:30 PM PT
Location: AACR (Free AACR Whitepaper) Annual Meeting 2026, San Diego, CA
"We are honored to contribute to this important educational session at AACR (Free AACR Whitepaper)," said Dr. Lu. "Our Logic-Gated cell therapies selectively kill cancer cells while protecting healthy cells. Enhanced therapeutic windows from Logic Gates enable the treatment of cancers for which conventional single-target biologics, such as T cell engagers and antibody-drug conjugates, and conventional single-target cell therapies are unable to perform. We look forward to sharing insights from our recent SENTI-202 clinical trial results in relapsed/refractory acute myeloid leukemia and other applications of our Logic Gates to improve precision and efficacy for cancer therapies."

The AACR (Free AACR Whitepaper) Annual Meeting is one of the leading global conferences for cancer research, bringing together scientists, clinicians, and industry leaders to discuss the latest advances in cancer science and medicine. For more information, please visit the conference website.

(Press release, Senti Biosciences, APR 13, 2026, View Source [SID1234664341])

On April 13, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that an oral podium presentation featuring colorectal cancer data for the company’s NeXT Personal ultrasensitive ctDNA assay and three posters will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting April 17-22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A focus of this year’s data is the introduction of a new NeXT Personal MRD test option, Real-Time Variant Tracker, a first-of-its-kind feature in tumor-informed clinical MRD testing, designed to longitudinally track therapy resistance mutations.

"We are thrilled to present the first NeXT Personal data on the Real-Time Variant Tracker. The AACR (Free AACR Whitepaper) data highlights how tracking therapy resistance mutations like ESR1 during MRD testing has the potential to inform patient management once cancer recurrence is detected," said Dr. Richard Chen, President and Chief Medical Officer at Personalis. "In addition, the data presented at AACR (Free AACR Whitepaper) further reinforces that ultrasensitive ctDNA detection with NeXT Personal can impact how colorectal cancer is monitored and managed. Both of these studies are examples of our unwavering commitment to innovation to drive better outcomes for patients."

Presentations at AACR (Free AACR Whitepaper) highlighting the use and clinical impact of the ultrasensitive NeXT Personal MRD test include:

Oral Podium Presentation: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response prediction.
Focus: Highlights the ultrasensitive ctDNA detection of NeXT Personal for predicting and tracking response to neoadjuvant immunotherapy in CRC patients.
Time: April 20, 2026, 2:35 PM–2:45 PM
Location: Room Hall H – Ground Level

Poster Presentation: Monitoring ESR1 and other mutations linked to resistance with a tumor-informed MRD test: Analytical validation and real world data.
Focus: Presents the analytical validation and real-world case studies of the new Real-Time Variant Tracker feature of NeXT Personal enabling detection of resistance and other clinical mutations during MRD testing.
Time: April 20, 2026, 9:00 AM–12:00 PM
Location: Section 46, Poster #2588

Poster Presentation: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data.
Focus: A deep analysis of the real-world clinical performance of NeXT Personal across a large patient cohort. The data highlights the ability for NeXT Personal to consistently achieve ultrasensitive ctDNA detection levels below 100 parts per million (ppm) and 10 ppm, across a diverse set of solid tumor types, stages, and challenging real-world testing conditions.
Time: April 20, 2026, 2:00 PM–5:00 PM
Location: Section 45, Poster #8225

Poster Presentation: Ultrasensitive ctDNA monitoring predicts early response of immunotherapy in recurrent metastatic non-small cell lung cancer.
Focus: Demonstrates the performance of NeXT Personal for predicting relapse and outcomes in advanced NSCLC patients receiving immunotherapy.
Time: April 20, 2026, 2:00 PM–5:00 PM
Location: Section 45, Poster #3851

(Press release, Personalis, APR 13, 2026, View Source [SID1234664340])

On April 13, 2026 Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, California. The presentations highlight Leukogene’s MHC class II engager lead development candidates in acute myeloid leukemia (AML) and pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first poster is titled "MHC class II engager immunotherapy for the treatment of acute myeloid leukemia (Poster Board #24, Poster #5552)".

The second poster is titled "MHC class II targeted immunotherapy in the treatment of pancreatic cancer (Poster Board #23, Poster #5551)".

These presentations will focus on an MHC class II-directed strategy in hematological cancers and solid tumors designed to recruit and activate anti-tumor immune cells, with the goal of converting immunologically "cold" tumors into more inflamed, "hot" lesions that respond better to immunotherapy. The company has developed a robust preclinical data package with evidence of single agent and combination efficacy, underscoring the potential of this approach to address a major unmet need in aggressive malignancies.

Both posters will be presented during the Immunology poster session titled "Bi- and Tri-Specific Antibody Therapies" on April 21, 2026, from 2:00 p.m. to 5:00 p.m. Pacific Time in Poster Section 6 at the San Diego Convention Center.

"Acute myeloid leukemia and pancreatic cancer remain among the most lethal and treatment‑resistant cancers, and there is a pressing need for more effective and durable therapies," said Sandeep Gupta, Ph.D., Chief Executive Officer of Leukogene Therapeutics. "These AACR (Free AACR Whitepaper) presentations emphasize the potential of our MHC class II-engager platform to reshape immune responses in both hematologic and solid tumors, and they represent an important step toward bringing new immunotherapy options to patients with limited choices."

(Press release, Leukogene Therapeutics, APR 13, 2026, View Source [SID1234664339])